Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | VEGFA | P15692 | 3/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406782 | 1.00 | IGF2R (0.48) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| SCHEMBL17479942 | 0.93 | GBA1 (0.53) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL2444941 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL2447683 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL21518298 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL2447224 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL2554532 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL2449290 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL2447696 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 | |
| Butylalphaman SCHEMBL93660 | 0.88 | MAPK1 (0.57) | IGF2RMAPK1LGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973145-B2 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | IGF2R 3102/4885MAPK1 2078/4885LGALS8 1840/4885 |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | IGF2R 3102/4885MAPK1 2078/4885LGALS8 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.